文献速递类风湿关节炎

中性粒细胞活化生物标志物组合在类风湿关节炎预后与监测中的价值

A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients With Rheumatoid Arthritis.
PubMed 文献 · Arthritis Rheumatol · 2019-12-03

该研究评估了血浆中性粒细胞活化(钙卫蛋白)与NETs形成标志物在类风湿关节炎(RA)中的临床价值。结果显示这些标志物在RA患者中显著升高,钙卫蛋白与疾病活动度相关并可区分缓解与活动期,生物标志物组合可预测侵蚀性疾病、关节间隙狭窄及关节外结节。

要点

  • 钙卫蛋白与CDAI相关(r=0.53,P<0.0001),可区分RA缓解与活动期。
  • 抗CCP抗体联合钙卫蛋白可预测侵蚀性疾病(OR 7.5,P<0.0001)和关节间隙狭窄(OR 4.9,P=0.001)。
  • NETs及中性粒细胞活化特征组合可预测关节外结节(OR 5.6,P=0.006)。

核心结论

  • RA中存在明显的中性粒细胞活化与细胞死亡,中性粒细胞标志物可为RA患者的监测和预后提供额外临床价值,并可能支持早期预防性治疗干预。

研究设计与样本

  • 研究在3个横断面RA队列及性别匹配的健康对照中,采用酶联免疫吸附试验分析血清和血浆中的中性粒细胞活化标志物(钙卫蛋白)和细胞死亡标志物(NETs)。
  • 采用一个纵向起始队列(n=247,中位随访8年)进行预测分析。

主要发现

  • RA患者的中性粒细胞活化与细胞死亡标志物较健康个体升高(P<0.0001)。
  • 钙卫蛋白水平与临床疾病活动指数相关(r=0.53,P<0.0001),可区分疾病缓解与活动期患者,而C反应蛋白水平无此观察结果。
  • 由抗瓜氨酸化蛋白抗体和钙卫蛋白组成的生物标志物组合可预测侵蚀性疾病(OR 7.5,P<0.0001)和关节间隙狭窄(OR 4.9,P=0.001)。
  • NETs水平与炎症标志物相关(P=0.0002)。
  • NETs和「中性粒细胞活化特征」生物标志物组合在识别发生关节外结节的患者方面具有良好预测价值(OR 5.6,P=0.006)。

关键数值与推荐

  • 钙卫蛋白与CDAI相关系数r=0.53(P<0.0001)。
  • 抗CCP抗体联合钙卫蛋白预测侵蚀性疾病OR 7.5(P<0.0001),预测关节间隙狭窄OR 4.9(P=0.001)。
  • NETs与炎症标志物相关P=0.0002;NETs及中性粒细胞活化特征组合预测关节外结节OR 5.6(P=0.006)。

临床怎么用

  • 钙卫蛋白可作为区分RA缓解与活动期的辅助监测指标,补充C反应蛋白的不足。
  • 抗CCP抗体联合钙卫蛋白的组合可用于评估侵蚀性疾病和关节间隙狭窄的预后风险。
  • NETs及中性粒细胞活化特征组合有助于识别发生关节外结节的高风险患者,可能支持早期预防性治疗干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs) are linked to inflammation and autoimmunity, including rheumatoid arthritis (RA). However, whether NETs are present in the circulation of RA patients and contribute to inflammation and disease progression has not been carefully addressed. We undertook this study to assess markers of neutrophil activation and NET formation in plasma samples, investigating whether they add clinical value in improving the determination of prognosis and monitoring in RA patients. METHODS: Markers of neutrophil activation (calprotectin) and cell death (NETs) were analyzed, using enzyme-linked immunosorbent assay, in serum and plasma obtained from patients in 3 cross-sectional RA cohorts and sex-matched healthy controls. A longitudinal inception cohort (n = 247), seen for a median follow-up of 8 years, was used for predictive analyses. RESULTS: Markers of neutrophil activation and cell death were increased in RA patients compared to healthy individuals (P < 0.0001). Calprotectin levels correlated with the Clinical Disease Activity Index (r = 0.53, P < 0.0001) and could be used to distinguish between patients with disease in remission and those with active disease, an observation not seen when examining C-reactive protein levels. A biomarker panel consisting of anti-citrullinated protein antibody and calprotectin could predict erosive disease (odds ratio [OR] 7.5, P < 0.0001) and joint space narrowing (OR 4.9, P = 0.001). NET levels were associated with markers of inflammation (P = 0.0002). Furthermore, NETs and a "neutrophil activation signature" biomarker panel had good predictive value in identifying patients who were developing extraarticular nodules (OR 5.6, P = 0.006). CONCLUSION: Neutrophils undergo marked activation and cell death in RA. Neutrophil biomarkers can provide added clinical value in the monitoring and prognosis of RA patients and may allow for early preventive treatment intervention.

来源:Arthritis Rheumatol,查看原文。版权归原作者所有。

引用

  1. Bach M, Moon J, Moore R, et al. A Neutrophil Activation Biomarker Panel in Prognosis and Monitoring of Patients With Rheumatoid Arthritis. Arthritis Rheumatol. 2019. PMID: 31353807. doi:10.1002/art.41062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。